Lakewood-Amedex Biotherapeutics, Inc. (LABT)
Nasdaq · Healthcare · Biotechnology
$0.8549−8.33%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $2.0M
- 52-week range
- $0.8227 – $98.20
- 52-week change
- −98.92%
- EPS (trailing)
- −$8.16
Fiscal year to Dec 2025
- Net income
- −$3.8M
- Diluted EPS
- −$8.40
From the company’s annual report on SEC EDGAR.
About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Headquarters: University Park, United States · 5 employees · lakewoodamedex.com